Clinical trials
Neuromyelitis Optica Spectrum Disorders (NMOSD) clinical trials
Below are recruiting neuromyelitis optica spectrum disorders (nmosd) clinical trials, each written for real people, not researchers. We’re tracking 34 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06374264Enrolling by invitation
Music-based walking therapy for NMOSD
This trial tests a music-based walking therapy (called MR-C-014) to see if it is safe and well-tolerated for people with NMOSD who have trouble walking. It may help improve your walking pattern and strength.
Atlanta, GeorgiaAges 18–70 - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age - NCT05966467Recruiting
Patient registry for AQP4+ neuromyelitis optica on C5 inhibitors
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05909761Recruiting
Pregnancy Uplizna safety study in women with NMOSD
This is an observational study that looks at the safety of Uplizna (satralizumab) during pregnancy for women who have neuromyelitis optica spectrum disorder (NMOSD). You may be asked to share information because your exposure to Uplizna happened during pregnancy or just before conception.
Aurora, ColoradoAges 15 years+ - NCT05549258RecruitingPhase 2
Inebilizumab for children with NMOSD who had recent relapses
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
La Jolla, CaliforniaAges 2–17 - NCT05504694RecruitingPhase 1/Phase 2
Ofatumumab for AQP4-positive NMOSD with recent relapses
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
Xi'an, ShaanxiAges 18 years+ - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT04886492Enrolling by invitation
NMOSD patient registry to help study future treatments
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
Waltham, MassachusettsAges 18 years+ - NCT06885957Recruiting
Monoclonal antibodies for AQP4-positive NMOSD
This trial is testing monoclonal antibody treatments for people with a specific type of neuromyelitis optica spectrum disorder (NMOSD) caused by AQP4 antibodies. It aims to see if these targeted therapies can help control the disease and prevent relapses.
Wuhan, HubeiAges 18–65 - NCT07087873Recruiting
Testing brain stimulation for memory problems in inflammatory diseases
This trial tests if a gentle electrical current applied to the scalp can improve memory and thinking in people with certain inflammatory conditions that affect the brain and spinal cord.
Beijing, Beijing MunicipalityAges 18–60
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuromyelitis optica spectrum disorders (nmosd)?
- Yes. Clin2 currently lists 34 recruiting neuromyelitis optica spectrum disorders (nmosd) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuromyelitis optica spectrum disorders (nmosd) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuromyelitis optica spectrum disorders (nmosd) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.